• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Zimmer Biomet Holdings Inc.

    5/27/26 5:00:02 PM ET
    $ZBH
    Industrial Specialties
    Health Care
    Get the next $ZBH alert in real time by email
    SD 1 zbh-20260526.htm SD SD


     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM SD

    Specialized Disclosure Report

     

    ZIMMER BIOMET HOLDINGS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

     

     

    Delaware

     

    001-16407

     

    13-4151777

    (State or other jurisdiction of

    incorporation)

     

    (Commission File Number)

     

    (I.R.S. Employer

    Identification No.)

    345 East Main Street

    Warsaw, Indiana 46580

    (Address of principal executive offices) (Zip Code)

     

    Chad F. Phipps

    Senior Vice President, Chief Legal and Corporate Affairs Officer and Secretary

    (574) 373-3333

    (Name and telephone number, including area code, of the person to contact in connection with this report.)

     

    Check the appropriate box to indicate the rule pursuant to which this form is being filed:

    ☑

    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2025.

    ☐

    Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended______ .

     

     


    Section 1 – Conflict Minerals Disclosure

     

    Item 1.01 Conflict Minerals Disclosure and Report

    This Form SD of Zimmer Biomet Holdings, Inc. (“Zimmer Biomet,” the “Company,” “we,” “our” or “us”) is filed pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for the reporting period from January 1, 2025 to December 31, 2025.

     

    Rule 13p-1 requires disclosure of certain information when a company manufactures or contracts to manufacture products and the minerals specified in the rule are necessary to the functionality or production of those products. The specified minerals are cassiterite, columbite-tantalite (coltan), gold, wolframite, or their derivatives, which are limited to tantalum, tin and tungsten (collectively, the “conflict minerals”).

     

    Conflict Minerals Disclosure

    We have adopted a policy statement on conflict minerals that is publicly available on our website at www.zimmerbiomet.com/corporate/suppliers.html.

     

    We design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic products; foot and ankle products; surgical products; bone cement; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. We have determined that certain of our products contain conflict minerals that are necessary to the functionality or production of those products (such minerals are referred to as “necessary conflict minerals”). We engaged iPoint, a third-party consultant, to assist with our reasonable country of origin inquiry and due diligence process for calendar year 2025. With the assistance of iPoint, we conducted a good faith inquiry of the supply base that was reasonably designed to determine whether any necessary conflict minerals contained in our products originated in the Democratic Republic of the Congo (“DRC”) or an adjoining country or were from recycled or scrap sources. As part of this inquiry, we conducted a supply chain survey of our direct suppliers using the iPoint Conflict Minerals Platform and the Conflict Minerals Reporting Template created and made available by the Responsible Minerals Initiative to collect sourcing information related to necessary conflict minerals in our products.

     

    Based on the results of our inquiry, we have reason to believe that some conflict minerals may have originated in the DRC or an adjoining country and may not be from recycled, scrap, or other country sources. Accordingly, we exercised due diligence on the source and chain of custody of such necessary conflict minerals, as described in the Conflict Minerals Report attached as Exhibit 1.01 to this Form SD.

     

    A copy of this Form SD, including the Conflict Minerals Report attached hereto as Exhibit 1.01, is publicly available on our website at www.zimmerbiomet.com (in the “Investors” section under the “Financial Information” caption and “SEC Filings” sub-caption).

     

    The content of any website referred to in this Form SD or the attached Conflict Minerals Report, and any information accessible through any such website, is included for general information only and is not incorporated by reference in this Form SD or the attached Conflict Minerals Report, nor deemed filed with the Securities and Exchange Commission.

     

    Item 1.02 Exhibit

     

    As specified in Section 3, Item 3.01, the Company is hereby filing its Conflict Minerals Report as Exhibit 1.01 to this Form SD.

     

    Section 2 – Resource Extraction Issuer Disclosure

     

    Item 2.01 Resource Extraction Issuer Disclosure and Report

     

    Not applicable

     

    Section 3 – Exhibits

     

    Item 3.01 Exhibits

     

     

     

     

    Exhibit No.

     

    Description

     

     

    1.01

     

    Conflict Minerals Report of Zimmer Biomet Holdings, Inc.

     


    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

     

    Date: May 27, 2026

     

     

     

    ZIMMER BIOMET HOLDINGS, INC.

     

     

    By:

     

    /s/ Chad F. Phipps

    Name:

     

    Chad F. Phipps

    Title:

     

    Senior Vice President, Chief Legal and Corporate Affairs Officer and Secretary

     


    Get the next $ZBH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZBH

    DatePrice TargetRatingAnalyst
    3/23/2026Buy → Neutral
    BTIG Research
    2/20/2026Mkt Perform
    William Blair
    1/9/2026$93.00Neutral → Sell
    Goldman
    1/6/2026Outperform → Mkt Perform
    Raymond James
    1/5/2026$210.00In-line → Outperform
    Evercore ISI
    12/16/2025$100.00Outperform → Neutral
    Robert W. Baird
    11/6/2025$100.00Overweight → Neutral
    Analyst
    9/18/2025$130.00Buy
    Rothschild & Co Redburn
    More analyst ratings

    $ZBH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Jafry Syed A. bought $223,641 worth of shares (2,135 units at $104.75), increasing direct ownership by 111% to 4,060 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    11/13/23 4:02:02 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Begley Christopher B bought $117,114 worth of shares (1,000 units at $117.11), increasing direct ownership by 39% to 3,540 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    9/29/23 4:05:41 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zimmer Biomet to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

    WARSAW, Ind., June 2, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8 with a fireside chat at 10:40 a.m. ET. A live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the fireside chat.About Zimmer BiometZimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize

    6/2/26 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2026

    WARSAW, Ind., May 22, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2026. The cash dividend of $0.24 per share is payable on or about July 31, 2026 to stockholders of record as of the close of business on June 25, 2026. About Zimmer BiometZimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessl

    5/22/26 4:30:00 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Increases Share Repurchase Expectations -- Up to $1 Billion by Year End

    WARSAW, Ind., May 12, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it now anticipates repurchasing up to $1 billion of its common stock during fiscal year 2026, a $250 million increase from the company's prior assumption. All repurchases are expected to be made under the company's existing $1.5 billion share repurchase authorization, which was approved by the Zimmer Biomet Board of Directors and announced in February 2026. The company has not made any changes to the size, duration or terms of that

    5/12/26 6:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    SEC Filings

    View All

    Zimmer Biomet Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

    5/27/26 5:30:16 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form SD filed by Zimmer Biomet Holdings Inc.

    SD - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

    5/27/26 5:00:02 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Zimmer Biomet Holdings Inc.

    SCHEDULE 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    5/15/26 10:07:47 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Officer Noor Jehanzeb

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    6/3/26 4:31:24 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Group President, Asia Pacific Yi Sang sold $413,216 worth of shares (5,000 units at $82.64), decreasing direct ownership by 16% to 27,251 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    6/2/26 4:35:23 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Director Farrell Michael J.

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    5/27/26 4:14:37 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zimmer Biomet downgraded by BTIG Research

    BTIG Research downgraded Zimmer Biomet from Buy to Neutral

    3/23/26 8:28:29 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    William Blair initiated coverage on Zimmer Biomet

    William Blair initiated coverage of Zimmer Biomet with a rating of Mkt Perform

    2/20/26 8:25:46 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet downgraded by Goldman with a new price target

    Goldman downgraded Zimmer Biomet from Neutral to Sell and set a new price target of $93.00

    1/9/26 8:52:52 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Leadership Updates

    Live Leadership Updates

    View All

    Zimmer Biomet Appoints Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer

    Experienced orthopedic surgeon from the Hospital for Special Surgery, innovator and former Chief Medical Technology Advisor joins company in an elevated capacityWARSAW, Ind., April 7, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Jonathan M. Vigdorchik, M.D., as Chief Science, Technology and Medical Affairs Officer, effective April 14. In this role, Dr. Vigdorchik will oversee the strategy, delivery, and management of the company's global end-to-end technology portfolio, including AI,

    4/7/26 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces New Chief Medical Advisors to Help Improve Standard of Musculoskeletal Care

    Dr. Jonathan M. Vigdorchik Named Chief Medical Technology Advisor, Adult Reconstruction and Hip Implants Dr. Anand M. Murthi Appointed Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.) WARSAW, Ind., Aug. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointments of Jonathan M. Vigdorchik, MD, as Chief Medical Technology Advisor focused on Adult Reconstruction and Hip Implants, and Anand M. Murthi, MD, FAAOS, as Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.). As strategic advisors, Drs. Vigdorchik and Murthi will leverage their extensive clinical experience t

    8/28/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas

    WARSAW, Ind., May 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kevin Thornal as Group President, Global Businesses and the Americas. Reporting to Chairman-Elect, President and CEO Ivan Tornos, Mr. Thornal will join the Company on July 1, 2025 to oversee the Americas commercial organization and lead business strategy and execution for its global Knees, Hips, S.E.T. and Data, Technology, and Enabling Solutions units. "Kevin is an incredible addition to our leadership team at an e

    5/27/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Financials

    Live finance-specific insights

    View All

    Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2026

    WARSAW, Ind., May 22, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2026. The cash dividend of $0.24 per share is payable on or about July 31, 2026 to stockholders of record as of the close of business on June 25, 2026. About Zimmer BiometZimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessl

    5/22/26 4:30:00 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces First Quarter 2026 Financial Results

    First quarter net sales of $2.087 billion increased 9.3% on a reported basis, 6.8% on a constant currency1 basis and 2.9% on an organic constant currency1 basisFirst quarter diluted earnings per share were $1.22, an increase of 34.1%; adjusted1 diluted earnings per share were $2.09, an increase of 15.5%Company updates full-year 2026 financial guidanceWARSAW, Ind., April 28, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2026.  The Company reported first quarter net sales of $2.087 billion, an increase of 9.3% over the prior year period, an increase of 6.8% on a constant currency1 basis and an increase of

    4/28/26 6:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2026 Financial Results

    WARSAW, Ind., April 9, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its first quarter earnings conference call will be webcast on Tuesday, April 28, 2026, at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. A live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call.Individuals in the U.S. and Canada who wish to dial int

    4/9/26 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

    SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    11/14/24 1:22:34 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zimmer Biomet Holdings Inc.

    SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    11/13/24 1:44:56 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

    SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    2/14/24 10:02:59 AM ET
    $ZBH
    Industrial Specialties
    Health Care